Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology
BIOGRAPHY
Speaker
Abstract
The prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%. It is considered a secondary form of hypertension caused by inappropriate secretion of aldosterone and activation of the mineralocorticoid receptor. As such, it is a highly treatable and potentially curable form of hypertension. This webinar will review the prevalence, pathophysiology, screening and diagnostic studies, and treatment options for patients with primary hyperaldosteronism so that the Practitioner can accurately screen and identify cases.
Learning objectives:
1. Understand the prevalence, pathophysiology and diagnostic studies for patients with primary hyperaldosteronism.
2. Be able to identify screening and treatment options for patients with primary hyperaldoseronism.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...